14 August 2019 - - US-based Schrödinger has expanded its computational design collaboration with biotechnology company Morphic Therapeutic, a biotechnology company focused on developing a new class of oral small-molecule integrin-targeted therapeutics that Schrödinger co-founded with Harvard Professor Timothy Springer, Ph.D., and Polaris Partners, the company said.

The expanded agreement, signed in May 2019, extends the partnership to discover and design therapeutic compounds leveraging Schrödinger's industry-leading computational platform.

Under the terms of the amended agreement, Schrödinger will receive research funding as well as milestone payments and licensing royalties on candidate compounds that emerge from the collaboration.

Through their partnership, Morphic and Schrödinger have accelerated the discovery and design of potent and selective integrin inhibitors and activators targeting serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Schrödinger technology informs Morphic's integrin technology, or MInT Platform, which leverages Morphic's unique understanding of integrin structure and biology to develop a pipeline of novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration.

Schrödinger's industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide.

In addition to this substantial and growing global business, Schrödinger has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.

Schrödinger's significant and ongoing investment in basic research continues to drive advances in its computational platform.

Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world.